Holen Sie sich die Stockscreener-App
3.91
15.00%
-0.69
Handel nachbörslich:
3.92
0.010
+0.26%
Artiva Biotherapeutics Inc Aktie (ARTV) Neueste Nachrichten
Artiva Leverages Unmodified NK Cells To Challenge CAR-T Paradigm - In Vivo
JPMorgan Chase & Co. Buys New Holdings in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Artiva Biotherapeutics appoints new director and committee members By Investing.com - Investing.com South Africa
Artiva Biotherapeutics expands board with industry veteran By Investing.com - Investing.com South Africa
Artiva Biotherapeutics expands board with industry veteran - MSN
Artiva Biotherapeutics appoints new director and committee members - Investing.com India
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. - GlobeNewswire
Former J&J Drug Development Chief Who Created Multi-Billion Dollar Therapies Joins Rising Biotech Board - StockTitan
Natural killer cells, a rising alternative to CAR-T cell therapy - Yahoo Finance
Brokerages Set Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Target Price at $21.00 - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Cantor Fitzgerald Predicts ARTV FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on ARTV FY2025 Earnings - MarketBeat
Barclays PLC Buys Shares of 19,616 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Artiva Biotherapeutics surges on trading debut - MSN
Artiva Biotherapeutics announces pricing of upsized $167M IPO - MSN
Aligos Therapeutics (NASDAQ:ALGS) & Artiva Biotherapeutics (NASDAQ:ARTV) Head to Head Contrast - Defense World
Artiva Biotherapeutics, Inc.'s Lock-Up Period To End on January 15th (NASDAQ:ARTV) - MarketBeat
Artiva Biotherapeutics, Inc.’s Lock-Up Period To Expire on January 15th (NASDAQ:ARTV) - Defense World
Geode Capital Management LLC Acquires Shares of 308,930 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
Geode Capital Management LLC Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Barclays PLC Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
State Street Corp Invests $1.34 Million in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
State Street Corp Acquires Shares of 86,559 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
What is HC Wainwright’s Estimate for ARTV FY2024 Earnings? - Defense World
Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $21.25 Average PT from Brokerages - Defense World
Research Analysts Issue Forecasts for ARTV FY2024 Earnings - MarketBeat
HC Wainwright & Co. Initiates Coverage of Artiva Biotherapeutics (ARTV) with Buy Recommendation - MSN
Artiva Biotherapeutics's SWOT analysis: NK cell therapy stock poised for growth - Investing.com India
Artiva Biotherapeutics’s SWOT analysis: NK cell therapy stock poised for growth - Investing.com Nigeria
Artiva Biotherapeutics (NASDAQ:ARTV) Now Covered by HC Wainwright - MarketBeat
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Benzinga
Franklin Resources Inc. Purchases Shares of 520,301 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
Nk Cell Therapy Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Artiva Biotherapeutics, Dragonfly therapeutics, Affimed, XNK Therapeut - Barchart
Nk Cell Therapy Pipeline 2024: Clinical Trials Assessment, FDA - openPR
BNP Paribas Financial Markets Invests $42,000 in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Charles Schwab Investment Management Inc. Invests $623,000 in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - Defense World
Wellington Management Group LLP Makes New Investment in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
Artiva Biotherapeutics's SWOT analysis: NK cell therapy stock poised for autoimmune breakthrough - Investing.com India
After Making the IPO Jump, Biotechs Landed On a Slippery Slope - BioSpace
RA Capital Management L.P. Purchases Shares of 9,853,302 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
291,666 Shares in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Purchased by Samsara BioCapital LLC - MarketBeat
RTW Investments LP Invests $2.30 Million in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
Acuta Capital Partners LLC Purchases Shares of 44,000 Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) - MarketBeat
1.03%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):